제2형 당뇨병 환자에서 Cerivastatin 단기 투여가 혈관내피세포 기능에 미치는 영향

Abstract

Background: Cardiovascular disease is the major cause of morbidity and mortality in patients with diabetes mellitus. Endothelial dysfunction is considered to be an early marker of atherosclerosis and cardiovascular risk. Beneficial cardiovascular effects of 3-hydroxy-3- methyglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) beyond cholesterol lowering may be at least partially due to its influence on endothelial function. In present study, we evaluated the effect of statins on endothelial function, independent of lipid-lowering. Methods: We enrolled 20 subjects (mean age, 55.0±9.39 years) with uncomplicated type 2 diabetes. All patients were taking 0.4 mg of cerivastatin (Lipobay, Byer Korea) for one week daily. We measured lipid profiles. Flow-mediated dilation (FMD) was measured using a high-resolution ultrasound. Results: After treatment with cerivastatin for one week, lipid profiles were not changed significantly, but the endothelium-dependent vasodilation of the brachial artery was increased. Conclusion: These results show that even short-term (1 week) cerivastatin treatment could improve the endothelial dysfunction without changes in lipid profiles in patients with type 2 diabetes mellitus.